Sugi Predict

Sugi Predict / Compounds / SCHEMBL758581

SCHEMBL758581

SCHEMBL758581

CC(C)(C)OC(=O)N[C@H]1C[C@H](C(=O)O)C1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.73
▸ KMT2A Q03164 2/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ KDM1A O60341 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ CTSK P43235 2/20 0.46
▸ GAA P10253 2/20 0.45
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ EPHX2 P34913 1/20 0.43
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ HSD11B1 P28845 1/20 0.42
▸ EPHX1 P07099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL668997 1.00 BTK (0.73) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL668998 1.00 BTK (0.73) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL14376238 0.98 BTK (0.71) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL7486096 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL540505 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL182101 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL1299320 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL1662045 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL895759 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL2564638 0.87 BTK (0.82) BTKKMT2AL3MBTL1KDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 — — EP disclosed
EP-4121421-B1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2026-03-11 — — EP disclosed
US-20260035335-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
US-20250313524-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-10-09 — — US disclosed
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2025-10-02 — — US disclosed
US-20250136591-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 — — EP disclosed
CN-119751461-A PKMYT1 inhibitor and preparation method and application thereof 中国药科大学 2025-04-04 — — CN disclosed
EP-4522596-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2025-03-19 — — EP disclosed
US-20250082614-A1 METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER CYTEIR THERAPEUTICS, INC. 2025-03-13 — — US disclosed
US-20100267669-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-10-21 — — US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 — — US disclosed
US-7790770-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-07 — — US disclosed
US-7790770-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-07 — — US disclosed
US-7790770-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-07 — — US disclosed
US-20090298894-A1 AMINO ACID COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2009-12-03 — — US disclosed
US-20090298894-A1 AMINO ACID COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2009-12-03 — — US disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 — — US disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 — — US disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313524-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF PIK3CA, PIK3CB, PIK3CD BTK 63/4885KMT2A 2974/4885L3MBTL1 3516/4885
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 BTK 1998/4885KMT2A 2236/4885L3MBTL1 2178/4885
US-20250082614-A1 METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER RAD51, MRE11, RAD52 BTK 3181/4885KMT2A 2280/4885L3MBTL1 1632/4885
US-20250136591-A1 RAD51 INHIBITORS RAD51, MRE11, RAD54L BTK 2586/4885KMT2A 1618/4885L3MBTL1 1142/4885
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 BTK 669/4885KMT2A 637/4885L3MBTL1 273/4885
US-20100267669-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 BTK 1998/4885KMT2A 2236/4885L3MBTL1 2178/4885
US-20260035335-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF PIK3CD, PIK3CG, PIK3CB BTK 63/4885KMT2A 3086/4885L3MBTL1 3206/4885
US-20090298894-A1 AMINO ACID COMPOUNDS S1PR1, S1PR2, S1PR5 BTK 1427/4885KMT2A 3063/4885L3MBTL1 1050/4885
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 BTK 3727/4885KMT2A 1686/4885L3MBTL1 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.